FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

		3 ⁽¹⁾			PROVAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMEN	T OF CHANGES IN BENEFICIAL OWN	ERSHIP	OMB Number: 3235-028 Estimated average burden			
 obligations may continue. See Instruction 1(b). 	Filed	pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940		hours per respons	e: 0.5		
1. Name and Address of Reporting Perso <u>Young Caroline</u>	n*	2. Issuer Name and Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS INC [CPIX]	5. Relationship of F (Check all applicab X Director Officer (gi	ble) 10	s) to Issuer 0% Owner ther (specify		
(Last) (First) 1600 WEST END AVENUE	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/25/2024	below)		below)		
SUITE 1300		4. If Amendment, Date of Original Filed (Month/Day/Year)	Line)	oint/Group Filing (Check Applicable ed by One Reporting Person			

Form filed by More than One Reporting Person

ity)	(State)	

TN

37203

(Zip)

Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	03/25/2024		A		1,000(1)	Α	\$1.71	26,701	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) o Dispo of (D (Instr	of Expiration Date Derivative (Month/Day/Year) Securities Acquired (A) or		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Restricted stock award will vest 100% on March 25, 2025.

Remarks:

Caroline Young by /s/ John

Hamm as attorney-in-fact

** Signature of Reporting Person Date

03/26/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

(Street)

(C

NASHVILLE